Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.

IF 3.6 3区 医学 Q2 HEMATOLOGY
Tina Nguyen, Tanya Markary, Ni-Chun Tsai, Katrin Tiemann, Sally Mokhtari, Yazeed Samara, Hoda Pourhassan, Amanda Blackmon, Shukaib Arslan, Salman Otoukesh, Vaibhav Agarwal, Idoroenyi Amanam, Brian Ball, Paul Koller, Ahmed Aribi, Amandeep Salhotra, Karamjeet Sandhu, Vinod Pullarkat, Pamela Becker, Ibrahim Aldoss, Haris Ali, Forrest Stewart, Eileen Smith, Anthony Stein, Guido Marcucci, Stephen J Forman, Andrew Artz, Ryotaro Nakamura, Monzr M Al Malki
{"title":"Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.","authors":"Tina Nguyen, Tanya Markary, Ni-Chun Tsai, Katrin Tiemann, Sally Mokhtari, Yazeed Samara, Hoda Pourhassan, Amanda Blackmon, Shukaib Arslan, Salman Otoukesh, Vaibhav Agarwal, Idoroenyi Amanam, Brian Ball, Paul Koller, Ahmed Aribi, Amandeep Salhotra, Karamjeet Sandhu, Vinod Pullarkat, Pamela Becker, Ibrahim Aldoss, Haris Ali, Forrest Stewart, Eileen Smith, Anthony Stein, Guido Marcucci, Stephen J Forman, Andrew Artz, Ryotaro Nakamura, Monzr M Al Malki","doi":"10.1016/j.jtct.2025.07.001","DOIUrl":null,"url":null,"abstract":"<p><p>Renal impairment is associated with poor outcomes following allogeneic hematopoietic cell transplantation (HCT). Although melphalan-based reduced-intensity conditioning (RIC) is demonstrated to be safe and feasible in older HCT patients, the impact of renal impairment on outcomes and toxicities following melphalan-based RIC is not well described. To evaluate how pretransplant renal function influences toxicity and survival after fludarabine/melphalan (FM) RIC and to compare measured 24-h urine creatinine clearance (UCrCl) with calculated creatinine-based renal function estimates as prognostic markers. Herein, we describe long-term outcomes of 561 HCT patients aged 55 to 74 years who received FM conditioning and tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis prior to matched donor HCT, between July 2009 and December 2019. Patients were divided based on pre-HCT UCrCl: creatinine clearance (CrCl) <90 mL/min (UCrCl 2 to 3, n = 184) and CrCl ≥90 mL/min (UCrCl 0 to 1, n = 377). CrCl for all patients was also calculated by the Cockcroft-Gault and the 2021 Chronic Kidney Disease Epidemiology Collaboration equations for comparison. UCrCl 2 to 3 correlated with higher 4-year non-relapse mortality (31% versus 19%, P < .01) and lower 4-year overall survival (55% versus 62%, P = .03) without differences in relapse rates. Neither CrCl calculation method correlated with any survival endpoint. UCrCl 2 to 3 was associated with higher severity and incidence of melphalan-related adverse events. Lower UCrCl was associated with less melphalan-induced severe GVHD- and gastrointestinal toxicity-free survival (MGTFS), a composite endpoint for severe melphalan-related morbidity and mortality at day +30 post-HCT and an early correlate of long-term survival outcomes (UCrCl 2 to 3: 18% versus UCrCl 0 to 1: 31%, P < .01). Patients with poor baseline UCrCl receiving melphalan-based RIC are at risk for significant conditioning-related toxicity and GVHD and, consequently, increased mortality. MGTFS quantified the early effect of FM RIC-related toxicities on post-HCT survival in this renally impaired HCT population.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2025.07.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Renal impairment is associated with poor outcomes following allogeneic hematopoietic cell transplantation (HCT). Although melphalan-based reduced-intensity conditioning (RIC) is demonstrated to be safe and feasible in older HCT patients, the impact of renal impairment on outcomes and toxicities following melphalan-based RIC is not well described. To evaluate how pretransplant renal function influences toxicity and survival after fludarabine/melphalan (FM) RIC and to compare measured 24-h urine creatinine clearance (UCrCl) with calculated creatinine-based renal function estimates as prognostic markers. Herein, we describe long-term outcomes of 561 HCT patients aged 55 to 74 years who received FM conditioning and tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis prior to matched donor HCT, between July 2009 and December 2019. Patients were divided based on pre-HCT UCrCl: creatinine clearance (CrCl) <90 mL/min (UCrCl 2 to 3, n = 184) and CrCl ≥90 mL/min (UCrCl 0 to 1, n = 377). CrCl for all patients was also calculated by the Cockcroft-Gault and the 2021 Chronic Kidney Disease Epidemiology Collaboration equations for comparison. UCrCl 2 to 3 correlated with higher 4-year non-relapse mortality (31% versus 19%, P < .01) and lower 4-year overall survival (55% versus 62%, P = .03) without differences in relapse rates. Neither CrCl calculation method correlated with any survival endpoint. UCrCl 2 to 3 was associated with higher severity and incidence of melphalan-related adverse events. Lower UCrCl was associated with less melphalan-induced severe GVHD- and gastrointestinal toxicity-free survival (MGTFS), a composite endpoint for severe melphalan-related morbidity and mortality at day +30 post-HCT and an early correlate of long-term survival outcomes (UCrCl 2 to 3: 18% versus UCrCl 0 to 1: 31%, P < .01). Patients with poor baseline UCrCl receiving melphalan-based RIC are at risk for significant conditioning-related toxicity and GVHD and, consequently, increased mortality. MGTFS quantified the early effect of FM RIC-related toxicities on post-HCT survival in this renally impaired HCT population.

基于melphalan的低强度异基因造血细胞移植治疗肾功能损害的疗效。
背景:肾损害与同种异体造血细胞移植(HCT)后的不良预后相关。尽管在老年HCT患者中,基于melphalan的降低强度调节(RIC)已被证明是安全可行的,但肾功能损害对基于melphalan的RIC后的预后和毒性的影响尚未得到很好的描述。目的:评估移植前肾功能如何影响氟达拉滨/美法兰(FM) RIC后的毒性和生存,并比较测量的24小时尿肌酐清除率(UCrCl)与计算的基于肌酐的肾功能评估作为预后指标。研究设计:本研究描述了2009年7月至2019年12月期间,561名55-74岁的HCT患者在匹配供体HCT之前接受FM调节和他克莫司/西罗莫司作为移植物抗宿主病(GVHD)预防的长期结果。结果:UCrCl 2-3与较高的4年非复发死亡率(NRM)相关(31% vs. 19%)。结论:基线UCrCl较差的患者接受基于melphalan的RIC治疗时存在显著的调节相关毒性和GVHD风险,因此死亡率增加。MGTFS量化了FM rics相关毒性对肾受损HCT人群HCT后生存的早期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信